Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
03/20/18Aerpio Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Mar. 20, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 3:00 p.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business ... 
Printer Friendly Version
03/15/18Aerpio Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Mar. 15, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that President and Founder, Joseph Gardner, Ph.D., will present at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 8:00 a.m. Eastern Time in New York, N.Y. Dr. Gardner will provide a corporate overview and business update. ... 
Printer Friendly Version
03/13/18Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call and Webcast Today, March 13th at 8:30 a.m. ET CINCINNATI--(BUSINESS WIRE)--Mar. 13, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017. ... 
Printer Friendly Version
03/07/18Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, March 13, 2018
CINCINNATI--(BUSINESS WIRE)--Mar. 7, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that its fourth quarter and full year 2017 financial results will be released before the market opens on Tuesday, March 13, 2018. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. Eastern Time to discuss the Company’... 
Printer Friendly Version
03/06/18Aerpio Pharmaceuticals to Present at the Cowen 38th Annual Health Care Conference
CINCINNATI--(BUSINESS WIRE)--Mar. 6, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Cowen 38th Annual Health Care Conference on Monday, March 12, 2018 at 2:50 p.m. Eastern Time in Boston, MA. Dr. Hoffman will provide a corporate overview and business upda... 
Printer Friendly Version
02/28/18Aerpio Pharmaceuticals Presents Analysis from TIME-2 Study Regarding Effects of AKB-9778 on Renal Function at 2018 Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ Injury
CINCINNATI--(BUSINESS WIRE)--Feb. 28, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced today that renal function data from the TIME-2 Phase 2a Study of AKB-9778 in the treatment of patients with diabetic macular edema (DME) was presented at the Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ Injury in Santa Fe, New Mexico. ... 
Printer Friendly Version
02/09/18Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
CINCINNATI--(BUSINESS WIRE)--Feb. 9, 2018-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced today the completion of patient enrollment in the company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate AKB-9778 for patients with moderate to severe non-proliferative diabetic ret... 
Printer Friendly Version